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tivecommons.org/licenses/by-nc-Summary Background: The aim of the present study was to demonstrate the antiulcer activ-
ity and mechanism of bezafibrate in a rat model of aspirin-induced gastric ulcer.
Methods: We used an aspirin-induced gastric ulcer model. Bezafibrate was administered orally
in graded doses (10 mg/kg, 25 mg/kg, 50 mg/kg, 100 mg/kg, and 200 mg/kg) to detect the best
effective antiulcer dose of bezafibrate. The parameters measured were: ulcer index, histo-
pathological scoring of gastric ulcer, gastric juice analysis, gastric mucosal lipid peroxidation
parameters, estimation of NO metabolite in blood, mRNA expression of inducible NO synthase
iNOS and constitutive NO synthase (cNOS) in gastric mucosa, and gastric mucosal DNA fragmen-
tation.
Results: The dose-dependent antiulcer activity of bezafibrate was shown by the ulcer index
and histopathological score. Bezafibrate (100 mg/kg) significantly reduced total acidity, free
acidity, and pepsin activity, and increased total hexoses and total proteins. Bezafibrate
(100 mg/kg) also significantly reduced lipid peroxidation, inhibited iNOS expression, preserved
cNOS expression, and inhibited DNA fragmentation.of Pharmacology, Post Graduate Institute of Medical Education and Research (PGIMER), Sector 12,
ail.com (L. Saha).
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102 L. Saha et al.Conclusion: Bezafibrate can decrease aspirin-induced gastric mucosal injury via reducing lipid
peroxidation, inhibiting iNOS expression, preserving cNOS expression, and decreasing DNA frag-
mentation.
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Peptic ulcer is a common disorder of the gastrointestinal
system and millions of people suffer from this disease
worldwide. The medical cost of treating peptic ulcer and its
complications amounts to billions of dollars annually. The
pathogenesis of peptic ulcer disease is multifactorial,
including Helicobacter pylori infection, chronic use of
nonsteroidal anti-inflammatory drugs, cigarette smoking,
alcohol, and reactive oxygen species (ROS) [1e3]. Peptic
ulcer is produced by the imbalance between gastroduo-
denal mucosal defense mechanisms and offensive factors
[4]. Recent studies also indicate that programmed cell
death or apoptosis plays a significant role in gastric ulcer-
ation [5e7]. Nitric oxide (NO) is a crucial mediator of
gastrointestinal mucosal defense, but, paradoxically, it also
contributes to mucosal damage [8]. This can be illustrated
by the ability of different NO concentrations to produce
completely opposite effects on the same tissue [9].
Nonsteroidal anti-inflammatory drugs such as aspirin is
widely used as an anti-inflammatory, analgesic drug and in
the prevention of cardiovascular events [10]. However, the
major limitations of their clinical application are serious
gastrointestinal side effects, especially peptic ulcerations
and gastrointestinal bleeding [11]. Studies have demon-
strated that the use of aspirin is associated with an
elevated risk of symptomatic peptic ulcer [12]. The risk of
peptic ulcer was elevated throughout treatment indepen-
dently of its duration, was elevated with doses as low as
75 mg/d, and was no different from that with doses of
150 mg/d and 300 mg/d [13,14].
Bezafibrate, a peroxisome proliferator activated recep-
tor (PPAR)a agonist, is often used in patients with diabetes
mellitus and dyslipidemia. These patients are also taking
aspirin for the prevention of cardiac events. So, we hy-
pothesized that if bezafibrate demonstrated antiulcer ac-
tivity against aspirin-induced gastric ulcer, then this
combination can be used in patients with diabetes mellitus
and dyslipidemia, with the additional benefit of the anti-
gastric ulcer effect of bezafibrate.
Studies in animals have demonstrated the gastric anti-
secretory activity of PPAR-a agonists like ciprofibrate,
bezafibrate, and clofibrate [15,16]. Eason et al. [16]
demonstrated significant inhibition of gastric secretion.
Pathak et al. [15] demonstrated the effect of PPAR-a
agonist, bezafibrate, on gastric secretion and gastric
cytoprotection in various gastric ulcer models in rats, such
as acetic-acid-induced chronic gastric ulcers, pylorus-
ligation-induced gastric ulcers, ethanol-induced gastric
ulcers, indomethacin-induced gastric ulcers, and ische-
miaereperfusion-induced gastric ulcers. However, in theaspirin-induced gastric ulcer model, the precise mecha-
nisms for antiulcer and gastric cytoprotective effects of
bezafibrate have not been studied.
To the best of our knowledge, no study has been carried
out to investigate the mechanism of the antigastric ulcer
effect of bezafibrate. Therefore, the present study was
contemplated with the aim of studying the mechanism of
bezafibrate as an antigastric ulcer agent. Keeping in view
the diversity of defensive mechanisms, the present study
was limited to exploring the oxidative stress, apoptosis, and
NO pathways and their involvement in the mechanism of
the antigastric ulcer effect of bezafibrate.
Methods
Experimental animals
Wistar rats of either genderweighing 200e250 gwere used for
the present study. The animals were obtained from Central
animal House, PGIMER, Sector 12, Chandigarh, India. The
animals weremaintained at 23 2C with a relative humidity
of 65 5% in a 12-hour light/dark cycle. The animals had free
access to standard pellet chow diet and tap water ad libitum.
The rats were acclimatized to laboratory conditions for at
least 7 days. Food was withheld for 36 hours and water for 1
hour prior to commencement of the study.
Grouping
A total of 60 animals was divided into 10 groups (IeX) of six
animals each as follows. Control Groups: Group I, normal
control (normal saline); Group II, saline þ aspirin (200 mg/
kg); and Group III, ranitidine (50 mg/kg) þ aspirin (200 mg/
kg). For a doseeresponse study of bezafibrate to establish
the best effective dose: Group IV, bezafibrate (10 mg/
kg) þ aspirin (200 mg/kg); Group V, bezafibrate (25 mg/
kg) þ aspirin (200 mg/kg); Group VI, bezafibrate (50 mg/
kg) þ aspirin (200 mg/kg); Group VII, bezafibrate (100 mg/
kg) þ aspirin (200 mg/kg); and Group VIII, bezafibrate
(200 mg/kg) þ aspirin (200 mg/kg). For mechanistic study
with best effective dose: Group IX, best effective dose of
bezafibrate (100 mg/kg) þ aspirin (200 mg/kg); and Group
X, L-NG-nitroarginine (L-NNA) (50 mg/kg) þ best effective
dose of bezafibrate (100 mg/kg) þ aspirin (200 mg/kg).
Ethical permission
Institutional Animal Ethics Committee (IAEC, PGIMER,
sector 12, Chandigarh) approval (No. 42/IAEC/163 dated
24.09.2008) was obtained before the start of the study and
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guidelines.
Drug treatment
Aspirin was suspended in 1% carboxymethyl cellulose and
administered orally at a dose of 200 mg/kg to produce
gastric ulcer in animals in Groups IIeX. Bezafibrate was
dissolved in dimethyl sulfoxide (50 mg/kg) and adminis-
tered at five different doses of 10 mg/kg, 25 mg/kg,
50 mg/kg, 100 mg/kg, and 200 mg/kg orally in animals of
Groups IVeVIII 30 minutes before aspirin. Ranitidine was
dissolved in water and given at a dose of 50 mg/kg orally
in animals of Group III 30 minutes before aspirin. L-NNA
(50 mg/kg) was dissolved in water and administered orally
30 minutes before bezafibrate (100 mg/kg) in animals of
Group X.
Aspirin-induced gastric ulcers and collection of
gastric juice
The animals were fasted for 24 hours before experimenta-
tion. They received water ad libitium. One hour before the
experiments, water was withheld. In animals of Groups
IVeVIII, bezafibrate was administered orally 30 minutes
before aspirin administration, and in Group III, ranitidine
was administered orally 30 minutes before aspirin admin-
istration (bezafibrate/ranitidine/aspirin/pyloric liga-
tion). In animals of Group X, L-NNA was administered orally
30 minutes before bezafibrate administration and 30 mi-
nutes after bezafibrate administration, aspirin was admin-
istered (L-NNA/bezafibrate/aspirin/pyloric ligation).
Thirty minutes after aspirin administration, animals were
anesthetized with pentobarbital (40 mg intraperitoneally),
the abdomen was opened, and the pyloric end of the
stomach was ligated with thread, taking care of the blood
vessels. The abdomen was closed and animals were kept
individually in the metabolic cage provided with a platform
with a wide mesh wire gauge to prevent coprophagy.
Gastric juice was allowed to collect for 4 hours after pyloric
ligation. After 4 hours pyloric ligation, rats were sacrificed
with pentobarbitone overdose. The abdomen was opened
and the cardiac end of the stomach was ligated. The
stomach was quickly dissected out and cut open along the
greater curvature and gastric juice was collected and
centrifuged (2500 g, 5 minutes) to obtain clear gastric
juice.
Doseeresponse study of bezafibrate to establish
the best effective dose
A doseeresponse study of bezafibrate was done by
administering five different doses (10 mg/kg, 25 mg/kg,
50 mg/kg, 100 mg/kg, and 200 mg/kg, orally) of bezafi-
brate in Groups IVeVIII. Bezafibrate was administered 30
minutes before aspirin administration. The doses of
bezafibrate were selected on the basis of the study of
Pathak el al [15]. The best effective dose of bezafibrate
was selected on the basis of ulcer index and histopatho-
logical score as follows.Ulcer index (damage score)
The damage score was assessed by grading the gastric
injury on a scale of 0 to 4 based on the severity of mucosal
hyperemia and hemorrhagic erosions according to Guha
et al. [17]: 0 Z almost normal mucosa; 0.5 Z hyperemia;
1 Z one or two hemorrhagic erosions; 2 Z severe hemor-
rhagic erosions; 3Z very severe hemorrhagic erosions; and
4 Z mucosa full of lesions (hyperemia, hemorrhagic ero-
sions, or vascular congestion).
Histopathological study of gastric lesions
Longitudinal sections were taken from the gastric lesion
(hyperaemia and erosions), along with the adjacent normal
gastric mucosa, of different sizes and subjected to histo-
pathological study using hematoxylin and eosin stain. The
scoring of the ulcer was done as follows: 0 Z no mucosal
changes; 1 Z changes limited to disruption of the surface
lining epithelium or superficial layer of the mucosa, with no
vascular congestion; 2 Z half of the mucosal thickness
showing tissue necrosis; 3 Z more than two-thirds of the
mucosal thickness destroyed, with marked tissue necrosis
and vascular congestion; the muscularis mucosae remained
intact; and 4 Z complete destruction of the mucosa with
necrosis and hemorrhage; muscularis mucosae not affected.
In the doseeresponse study groups (IVeVIII), both gastric
juice and tissue antioxidant parameters were analyzed.
Mechanistic study with best effective dose of
bezafibrate (100 mg/kg)
Based on the ulcer index and histopathological scores,
bezafibrate 100 mg/kg body weight, was selected as best
effective dose. The detailed mechanistic studies were done
in Groups IX and X as follows.
Analysis of gastric juice for offensive/defensive
factors
Free and total acidity was estimated by the method of
Mallika et al. [18], and was expressed as mEq/h. Pepsin
activity was measured according to the method of Newaz
et al. [19]. Total hexoses were estimated by the method of
Dische and Borenfreud [20] and expressed as mg/mL. Mucin
content was estimated by the method of Sanyal et al. [21]
and expressed as mg/g. Protein content was estimated by
the method of Lowry et al. [22] and expressed as mg/mL.
Assessment of oxidative-stress-related parameters
The stomach tissue was homogenized in 50mM phosphate
buffer (pH 7.2)/150mM NaCl (phosphate-buffered saline) at
4C using a glasseteflon homogenizing tube. The homoge-
nate was centrifuged (2500 g, 10 minutes). The supernatant
was used for assessment of oxidative-stress-related
parameters.
Tissue lipid peroxidation was evaluated by measure-
ment of thiobarbituric acid reactive substances according
to the method of Ohkawa et al. [23]. Superoxide
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[24]. Activity of the catalase was measured using the
method of Luck [25]. Assay of reduced glutathione was
performed in tissue homogenates by the method of Griffith
[26]. For estimation of NO metabolite, 0.5 mL of blood was
collected from each anesthetized animal by cardiac
puncture and subjected to estimation of nitrate level by
the method of Green et al. [27].
Reverse-transcriptase polymerase chain reaction
for inducible NO synthase mRNA in gastric mucosa
Total RNA was extracted from gastric mucosal samples by
the method of Chomczynski and Sacchi [28]. RNA samples
were stored at 80C until analysis. Single-stranded cDNA
was generated from 5 mg total cellular RNA by reverse
transcriptase and oligo-(dT)- primers. Five micrograms of
total RNA was uncoiled by heating (65C for 5 minutes)
and then reverse transcribed into cDNA. The resultant
cDNA (2 mL) was amplified in a 50-mL reaction volume
containing 2 U Taq polymerase, dNTP (200mM each),
1.5mM MgCl2, 5 mL 10 polymerase chain reaction (PCR)
buffer [10mM Tris/HCl (pH 8.3)/50mM KCl] and specific
primer was used at a final concentration of 0.5mM. The
PCR mixture was amplified in a DNA thermal cycler. The
nucleotide sequences of the primer for inducible NO
synthase (iNOS), constitutive NO synthase (cNOS), and b
actin were based on the published cDNAs sequences
(iNOS: sense 50 CAG TGG CAA CAT CAG GTC and antisense
30 GGT CTC GGA CTC CAA TCT, for cNOS: sense 50 TAC TTG
AGG ATG TGG CTG and antisense 30 GTC TTC TTC CTG GTG
ATG, for b actin: sense 50 TTG TAA CCA ACT GGG ACG ATATable 1 Ulcer index, histopathological scores, and gastric juice
Groups Ulcer index Histopathological
scores Free
(mE
Saline control 0.03  0.01 0.33  0.09 3.66
Aspirin þ saline 0.33  0.04* 2.83  0.28* 8.29
Ranitidine þ aspirin 0.04  0.02** 1.5  0.02** 4.89
Bezafibrate
10mg/kg þ aspirin
0.14  0.03* 2.0  0.08* 7.05
Bezafibrate 25
mg/kg þ aspirin
0.10  0.04* 2.1  0.05* 6.93
Bezafibrate 50
mg/kg þ aspirin
0.09  0.02** 1.8  0.06** 6.10
Bezafibrate 100
mg/kg þ aspirin
0.04  0.03** 1.0  0.05** 5.50
Bezafibrate 200
mg/kg þ aspirin
0.09  0.04** 1.6  0.08** 5.86
LNNA þ bezafibrate 100
mg/kg þ aspirin
0.24  0.09*** 2.00  1.78*** 7.61
Data are expressed as mean  standard error; n Z 6 in each group.
* p < 0.05 as compared to saline control group.
** p < 0.05 as compared to aspirin-treated group.
*** p < 0.05 as compared to bezafibrate 100 mg/kg group.
LNNA Z L-NG-nitroarginineTGG and antisense 30 GAT CTT GAT CTT CAT GGT GCT
AGG). A PCR product was detected by electrophoresis on a
1.5% agarose gel containing ethidium bromide. Location of
predicted products was confirmed by using 100-bp ladder
as a standard size marker.
Gastric mucosal DNA fragmentation study
DNA from gastric mucosa was isolated by phenolechloro-
form extraction method and subjected to agarose gel
electrophoresis. DNA ladder/smearing, if any, was visual-
ized by UV-transilluminator and photographed.
Statistical analysis
Statistical analysis was assessed using one-way analysis of
variance followed by Bonferroni comparison test. Ulcer
index and histopathological scores were compared by
ManneWhitney U test. The values are expressed as
mean  standard deviation and p < 0.05 was considered
statistically significant.
Results
Effect of bezafibrate on aspirin-induced gastric
ulcer and ulcer index
The macroscopic findings of the opened stomach showed
that hemorrhagic gastric ulcers covered with coagulated
blood were more apparent in the aspirin group than the
control group. Coadministration of bezafibrate 100 mg/kganalysis in controls and experimental groups.
Gastric juice analysis
acidity
q/L)
Total acidity
(mEq/L)
Total
hexoses
(mg/mL)
Total
proteins
(mg/mL)
 1.24 8.81  0.99 4.16  1.32 79.96  3.92
 1.42* 13.76  2.13* 2.75  1.05 49.48  4.27*
 0.45** 10.79  0.67** 5.10  0.43 77.07  3.16**
 1.23* 12.32  1.13* 3.14  0.78 64.79  1.16*,**
 0.56* 12.12  0.57* 3.34  0.74 64.36  1.4*,**
 0.71*,** 11.29  0.67*,** 3.87  0.52 65.81  1.3*,**
 0.53*,** 10.65  1.31** 4.49  0.58 69.58  2.36*,**
 0.86*,** 11.66  0.54* 4.27  0.21 68.95  2.24*,**
 1.02*** 11.87  1.11*** 3.74  1.28 56.44  3.29***
Figure 1 (A) Effect of graded doses of bezafibrate on ulcer index. (B) Effect of graded doses of bezafibrate on histopathological
scores. Data are expressed as mean  standard error (n Z 6).
Role of bezafibrate in rat model of gastric ulcer 105with aspirin inhibited aspirin-induced ulcer formation.
Table 1 shows the effects of bezafibrate given in graded
doses ranging from 10 mg/kg to 200 mg/kg intraperitoneally
on the ulcer index in the rat model of aspirin-induced
gastric ulcer. Aspirin caused a significant increase in the
ulcer index as compared to that of the saline treated con-
trol group of animals. Administration of bezafibrate was
associated with a significant decrease in the ulcer index
compared to aspirin alone (Figure 1A and Table 1). The
most pronounced effect on ulcer index was observed at a
dose of 100 mg/kg bezafibrate and this dose was used for
further mechanistic studies. L-NNA pretreatment caused
significant antagonism of the effect of bezafibrate (100 mg/
kg) on the ulcer index (Table 1).Histopathological findings of gastric mucosa and
scoring
The gastric mucosa obtained from the control rats showed
normal mucosa, submucosa, muscularis and serosa. Aspirin
administration showed ulcer formation with distorted
gastric glands, and damaged mucosal epithelium and cell
debris; however, coadministration of bezafibrate (100 mg/
kg) with aspirin protected against these changes. Table 1 and
Figure 1B show the effects of graded doses of bezafibrate on
the histopathological scores in aspirin-induced gastric ulcer.
Administration of bezafibrate along with aspirin was associ-
ated with a significant decrease in the histopathological
scores at a dose of 100 mg/kg and 200 mg/kg as compared to
106 L. Saha et al.aspirin alone. Themost pronounced effect was observed at a
dose of 100 mg/kg bezafibrate. L-NNA pretreatment antag-
onized the effect of bezafibrate (100 mg/kg) on the histo-
pathological score (Table 1).
Effect of bezafibrate on gastric juice parameters
Table 1 shows the effect of graded doses of bezafibrate on
the defensive and aggressive factors in gastric juice in the
rat model of aspirin-induced gastric ulcer. Bezafibrate (þ
aspirin) at higher doses (50 mg/kg, 100 mg/kg, and 200mg/
kg) and ranitidine (þ aspirin) showed significant reductions
in the free and total acidity as compared to aspirin alone.
All of the doses of bezafibrate and ranitidine produced a
significant increase in total proteins as compared to aspirin
alone (Table 1). None of the doses of bezafibrate produced
any significant effect on total hexoses. The most pro-
nounced effect on gastric juice parameters was observed at
a dose of 100 mg/kg bezafibrate. LNNA pretreatment
caused significant antagonism of the effects of bezafibrate
(100 mg/kg) on all of the parameters except total hexoses
(Table 1).
Effect of graded doses of bezafibrate on gastric
mucosal lipid peroxidation and antioxidant system
Table 2 shows the effect of graded doses of bezafibrate on
the gastric mucosal lipid peroxidation and antioxidant sys-
tem. All the doses of bezafibrate and ranitidine showed
significant decrease in malondialdehyde level and signifi-
cant increase in SOD activity and reduced glutathione as
compared to the aspirin-treated group. BezafibrateTable 2 Effect of graded doses of bezafibrate on gastric mucosa
rat model of aspirin-induced gastric ulcer.
Groups MDA
concentration
(nmol/mg
tissue)
SOD activity
(U/g tissue)
Catal
(mmo
deco
/mg
Saline control 9.24  0.11 366.84  6.32 7.65
Aspirin þ saline 14.30  0.46* 263.18  7.34* 6.78
Ranitidine þ aspirin 8.76  0.44** 316.25  4.54*,** 5.71
Bezafibrate
10 mg/kg þ aspirin
12.45  0.64*,** 322.68  5.14*,** 6.73
Bezafibrate
25 mg/kg þ aspirin
11.60  0.46*,** 326.54  3.23*,** 6.94
Bezafibrate
50 mg/kg þ aspirin
10.79  0.67*,** 340.65  9.12*,** 6.90
Bezafibrate
100 mg/kg þ aspirin
10.29  1.01** 356.52  3.26** 7.72
Bezafibrate
200 mg/kg þ aspirin
11.53  0.32*,** 343.25  5.53*,** 6.85
LNNA þ Bezafibrate
100 mg/kg þ aspirin
12.9  1.11*** 295.50  4.99*** 6.94
Data are expressed as mean  standard error.
* p < 0.05 compared to the saline control group.
** p < 0.05 compared to the aspirin group.
*** p < 0.05 as compared to the bezafibrate 100 mg/kg group.
LNNA Z L-NG-nitroarginine.(100 mg/kg) showed a significant increase in catalase ac-
tivity. LNNA pretreatment caused significant antagonism of
the antioxidant effect of bezafibrate (100 mg/kg; Table 2).
Effect of bezafibrate on plasma nitrate level
Table 2 shows the effect of bezafibrate (100mg/kg) alone and
bezafibrate (100 mg/kg) þ LNNA on plasma levels of the NO
metabolite, nitrate, in aspirin-induced gastric ulcer in rats. In
the aspirin-induced gastric ulcer group, there was a signifi-
cant increase in plasma nitrate as compared to the saline
control group (Table 2). When bezafibrate (100 mg/kg) was
coadministered with aspirin there was a decrease in plasma
nitrate level as compared to the aspirin-treated group. Pre-
treatment with LNNA did not cause a significant change in
plasma nitrate level as compared to the saline control and
bezafibrate (100 mg/kg) þ aspirin-treated groups.
Effect of bezafibrate on mRNA expression of iNOS
and cNOS in gastric mucosa
Figures 2 and 3 show the expression of mRNA of iNOS and
cNOS in gastric mucosa. iNOS mRNA expression (Figure 2)
was detected in the gastric mucosa of control animals.
Following administration of aspirin, the ratio of iNOS to
b-actin increased significantly, indicating that mRNA
expression of iNOS was significantly upregulated by aspirin.
In animals treated with bezafibrate (100 mg/kg) þ aspirin,
and LNNA þ bezafibrate (100 mg/kg) þ aspirin, this in-
crease in iNOS protein expression was significantly attenu-
ated, but was still higher than in the control animals
(Figure 2).l lipid peroxidation and antioxidant system and nitrate level in
ase activity
l of H2O2
mposed/min
protein)
GSH-Px activity
(m mol/min/mg
protein)
Reduced
glutathione
(nM/mg
protein)
Plasma
nitrate
(mg/mL)
 0.21 60.39  0.62 75.05  0.52 22.83  2.08
 0.10* 55.48  0.24* 55.28  1.13* 28.37  2.98*
 0.25*,** 64.11  1.12*,** 61.87  1.34*,** -
 0.35* 58.97  2.32 59.17  1.37*,** -
 0.21* 59.15  2.03** 60.93  1.27*,** -
 0.36* 59.87  1.73** 65.06  1.21*,** -
 0.97** 64.63  1.24*,** 72.94  1.56** 23.33  3.10
 0.65* 63.20  1.10** 67.20  2.01*,** -
 0.23*** 56.66  1.20*** 58.74  6.99*** 22.86  1.99
Figure 2 Expression of mRNA for iNOS by reverse transcriptase polymerase chain reaction in gastric mucosa and the ratio of iNOS
to b-actin mRNA in (1) control group, (2) aspirin group, (3) aspirin þ bezafibrate 100 mg/kg group, and (4) aspirin þ bezafibrate
100 mg/kg þ L-NG-nitroarginine group in the upper panel. 1 Z saline control; 2 Z aspirin þ saline; 3 Z bezafibrate
100 mg/kg þ aspirin; 4 Z LNNA þ bezafibrate 100 mg/kg þ aspirin; iNOS Z inducible NO synthase in the bar diagram.
Figure 3 Expression of mRNA for cNOS by reverse transcriptase polymerase chain reaction in gastric mucosa and the ratio of cNOS
to b-actin mRNA in (1) control group, (2) aspirin group, (3) aspirin þ bezafibrate 100 mg/kg group, and (4) aspirin þ bezafibrate
100 mg/kg þ L-NG-nitroarginine group in the upper panel. 1 Z saline control; 2 Z aspirin þ saline; 3 Z bezafibrate
100 mg/kg þ aspirin; 4 Z LNNA þ bezafibrate 100 mg/kg þ aspirin; cNOS Z constitutive NO synthase in the bar diagram.
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Figure 4 Agarose gel electrophoresis for qualitative esti-
mation of DNA fragmentation in different experimental groups.
Lane DLZ DNA fragment size marker indicating 100e2000 base
pairs; Lanes 1e4Z DNA fragments in the control group; Lanes
5e8 Z DNA fragments in aspirin group; Lanes 9 and 10 Z DNA
fragments in bezafibrate 100 mg/kg þ aspirin group; Lanes 11
and 12 Z DNA fragments in L-NG-nitroarginine þ bezafibrate
100 mg/kg þ aspirin group.
108 L. Saha et al.In all the control animals, cNOS was detected as a strong
signal (Figure 3). Treatment with aspirin resulted in down-
regulation of mRNA expression for cNOS. In animals treated
with bezafibrate (100 mg/kg) þ aspirin and
LNNA þ bezafibrate (100 mg/kg) þ aspirin, downregulation
of mRNA expression of cNOS was not as prominent as with
aspirin alone, however, expression was less than in the
control group (Figure 3).
Effect of bezafibrate on DNA fragmentation in
gastric mucosa
DNA extracted from gastric mucosa was subjected to
agarose gel electrophoresis for qualitative estimation of
DNA fragmentation. Figure 4 shows the DNA fragmentation
in different experimental groups. Lane DL is a DNA frag-
ment size marker indicating 100e2000 base pairs; Lanes
1e4 show DNA fragments in the control group; Lanes 5e8
show DNA fragments in the aspirin alone group; Lanes 9 and
10 show DNA fragments in the bezafibrate 100 mg/
kg þ aspirin group; and Lanes 11 and 12 show DNA frag-
ments in the LNNA þ bezafibrate 100 mg/kg þ aspirin
group. No ladder pattern was seen in the control group,
suggesting there was no mucosal damage (Lanes 1e4). The
aspirin-induced gastric ulcer group showed a laddering
pattern with the formation of a large number of fragments
ranging from 1517 base pairs to 100 base pair fragments,
indicating DNA fragmentation (Lanes 5e8). Bezafibrate
(100 mg/kg) þ aspirin, and LNNA þ bezafibrate (100 mg/
kg) þ aspirin groups had minimal DNA fragmentation, sug-
gested by formation of fewer bands as compared to the
aspirin-induced ulcer group (Lanes 9e12).
Discussion
We demonstrated that bezafibrate, a PPARa agonist, dose
dependently produced antiulcer activity in a rat model ofaspirin-induced gastric ulcer. Bezafibrate significantly
decreased the total acidity and free acidity in the gastric
juice. The total protein in the gastric juice was increased
with bezafibrate treatment. Our results suggest that
bezafibrate has both gastric antisecretory and gastro-
protective effects and these results are consistent with
previous reports with bezafibrate, ciprofibrate, and clofi-
brate [15,16]. The present study histopathologically
demonstrated the protective effect of bezafibrate on
gastric mucosal injury induced by aspirin.
Ranitidine (50 mg/kg) was used as a positive control in
the present study. The effect of ranitidine on ulcer index,
histopathological scoring, and gastric juice parameters like
total acidity, free acidity, total protein, and total hexoses
were comparable to those of 100 mg/kg bezafibrate. This
effect of ranitidine on aspirin-induced gastric ulcer has also
been demonstrated by Nair et al. [29].
The mechanistic studies with the best effective dose of
bezafibrate (100 mg/kg) were also performed by exploring
the mucosal lipid peroxidation and antioxidant system,
apoptosis pathway, and NO pathway. Bezafibrate attenu-
ated aspirin-induced gastric mucosal injury by significantly
inhibiting thiobarbituric acid-reactive substance produc-
tion, an index of lipid peroxidation, and inducing the anti-
oxidant system, as there were increases in SOD activity,
catalase activity and reduced glutathione level in the
gastric mucosa. The results of the present study are in
accordance with those of Naito et al. [30]. In this study,
ranitidine also showed antioxidative effects similar to
100 mg/kg bezafibrate. The antioxidative effect of raniti-
dine has also been studied by Nair et al. [29]. Previous
studies have demonstrated that the therapeutic effects of
H2 blockers on peptic ulcers might be related to their
antiradical/antioxidant capacity, suggesting that these
drugs could be used for treatment of other diseases that are
characterized by free-radical-mediated oxidative stress
[31e33]. Ching et al. [32] showed that H2 blockers were
also powerful hydroxyl radical scavengers. Another study
showed that H2 blockers had powerful scavenging effects
on hypochlorous acid and monochloramine, which arise
from inflammatory cells such as neutrophils [33].
Programmed cell death or apoptosis plays a significant role
in gastric ulcer formation as demonstrated in previous studies
[5e7]. In the present study, apoptosis was seen in the aspirin-
treated gastric mucosa as there was a formation of a large
number of DNA fragments in agarose gel electrophoresis.
However, less DNA fragmentation (apoptosis) was seen in the
bezafibrateþ aspirin (100 mg/kg) group, as there were fewer
bands formed in agarose gel electrophoresis of the gastric
mucosa as compared to the aspirin alone group.
One of the mechanisms by which aspirin damages the
gastric mucosa is the increased production of NO due to
overexpression of iNOS [34]. NO is a mediator not only of
gastrointestinal mucosal defense [35] but also of its damage
[8]. It has been shown that different concentrations of NO
have completely opposite effects on the same tissue [9]. In
general, the mucosal and endothelial NOS isoforms produce
low amounts of NO. However, the high quantity of NO
produced by iNOS damages the epithelium [9,33,36]. The
excessive release of NO from gastric epithelial cells induced
by aspirin has been reported to exert detrimental effects
[37,38]. The present study demonstrates that one of the
Role of bezafibrate in rat model of gastric ulcer 109important mechanisms by which aspirin damages gastric
mucosa is increased production of NO due to overexpression
of iNOS. The excessive NO release has been reported to
exert detrimental effects attributed to reactive nitrogen
species, such as oxides of nitrogen and peroxynitrate,
which are formed by the reaction of NO with oxygen and
superoxide, respectively [39]. The addition of bezafibrate
(100 mg/kg) to aspirin attenuated the plasma nitrate level,
decreased the expression of iNOS, and prevented the
decrease in cNOS expression in gastric mucosa. A similar
result was demonstrated by Konturek et al. [40] with pio-
glitazone, a PPAR g agonist. The mechanism by which
bezafibrate attenuates iNOS expression and preserves cNOS
expression remains to be clarified in further studies.
In conclusion, bezafibrate, a PPAR-a agonist, demon-
strated dose-dependent antiulcer activity in rats. Bezafi-
brate also demonstrated antisecretory and
gastroprotective action, reduced lipid peroxidation,
inhibited iNOS expression, preserved cNOS expression, and
inhibited DNA fragmentation in gastric mucosa. All these
actions of bezafibrate contribute to its antiulcer effect in a
rat model of aspirin-induced gastric ulcer. Therefore,
bezafibrate, a hypotriglyceredemic agent, protects against
aspirin-induced gastric ulcer in a rat model.
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